VERA is trading at $41.00 (4.6% down) in pre-market as investors lock in gains following the FDA's accelerated approval of its IgA nephropathy drug, atacicept (Trutakna).
- Shares had previously rallied more than 8% on the announcement of the regulatory milestone for the company's lead candidate.
- Today's decline appears to be a recalibration following the initial surge, compounded by broader weakness across the equity markets in pre-market trading.